TriangleNab-paclitaxel + Gemcitabine (NCT07043270)
Nab-paclitaxel + Gemcitabine trial for Pancreas Adenocarcinoma (NCT07043270). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with borderline-resectable pancreatic adenocarcinoma without prior chemotherapy or radiation for it. BRCA1, BRCA2, or PALB2 mutations exclude participation.
The idea: chemotherapy combinations alternate in four-week cycles before planned surgery. Gemcitabine, which disrupts DNA production, plus nab-paclitaxel is given in cycles one and three; modified FOLFIRINOX is given in cycles two and four. Researchers test whether this sequence improves tumor removal and one-year freedom from cancer events or death.
This phase 2 study plans 35 patients. Dartmouth-Hitchcock sponsors it in Lebanon, New Hampshire, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.